Crossmark

A call back to reality!

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2014.226

Published Online: 2015-01-06

Published Print: 2015-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cardoso, Fatima

Senkus, Elżbieta
License Information

Text and Data Mining valid from 2015-01-06
More Information

Article History

First Online: 6 January 2015

Competing interests

: F.C. serves as a consultant and receives honoraria from Astella, AstraZeneca, BV, Celgene, Daiichi Sankyo, Eisai, GE oncology, Genentech/Roche, GlaxoSmithKline, Merck-Sharp Dohme, Merus, Novartis, Pfizer, Prime Oncology, Sanofi. E.S is an advisory board member of AstraZeneca, Genentech/Roche, GlaxoSmithKline and Teva; E.S. receives travel support from Amgen, Novartis and Genentech/Roche, and is speaker's bureau for AstraZeneca, Genentech/Roche and GlaxoSmithKline.